SG11201510618YA - Regulation of glucose metabolism using anti-cgrp antibodies - Google Patents
Regulation of glucose metabolism using anti-cgrp antibodiesInfo
- Publication number
- SG11201510618YA SG11201510618YA SG11201510618YA SG11201510618YA SG11201510618YA SG 11201510618Y A SG11201510618Y A SG 11201510618YA SG 11201510618Y A SG11201510618Y A SG 11201510618YA SG 11201510618Y A SG11201510618Y A SG 11201510618YA SG 11201510618Y A SG11201510618Y A SG 11201510618YA
- Authority
- SG
- Singapore
- Prior art keywords
- regulation
- glucose metabolism
- cgrp antibodies
- cgrp
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842745P | 2013-07-03 | 2013-07-03 | |
| US201461982611P | 2014-04-22 | 2014-04-22 | |
| PCT/US2014/045389 WO2015003122A2 (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510618YA true SG11201510618YA (en) | 2016-03-30 |
Family
ID=52144290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510618YA SG11201510618YA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
| SG10201906172XA SG10201906172XA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906172XA SG10201906172XA (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017166A1 (en) * | 2013-07-03 | 2015-01-15 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| EP4196611A1 (en) * | 2020-08-15 | 2023-06-21 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
| CN117813325A (zh) | 2021-08-27 | 2024-04-02 | H.隆德贝克有限公司 | 使用抗cgrp抗体治疗丛集性头痛 |
| WO2025262247A1 (en) | 2024-06-21 | 2025-12-26 | H. Lundbeck A/S | Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| DE68924372T2 (de) * | 1988-01-11 | 1996-05-09 | Amylin Pharmaceuticals Inc | Behandlung von diabetes mellitus typ 2. |
| US5266561A (en) * | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| US5364841A (en) * | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE68923790T2 (de) * | 1989-01-03 | 1996-05-15 | Motorola Inc | Verfahren zum herstellen von löthöckern hoher dichte und ein substratsockel für löthöcker hoher dichte. |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| IE71195B1 (en) * | 1989-07-10 | 1997-02-12 | Amylin Corp | Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| EP1461068A4 (en) * | 2001-11-26 | 2006-03-29 | Protemix Corp Ltd | METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| NZ601583A (en) | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EA033109B1 (ru) * | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| US20150017166A1 (en) * | 2013-07-03 | 2015-01-15 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
-
2014
- 2014-07-03 US US14/323,028 patent/US20150017166A1/en not_active Abandoned
- 2014-07-03 MX MX2016000220A patent/MX374612B/es active IP Right Grant
- 2014-07-03 WO PCT/US2014/045389 patent/WO2015003122A2/en not_active Ceased
- 2014-07-03 TW TW103122993A patent/TWI712419B/zh active
- 2014-07-03 EP EP14820173.4A patent/EP3016684B1/en active Active
- 2014-07-03 CA CA2916980A patent/CA2916980C/en active Active
- 2014-07-03 IL IL243355A patent/IL243355B2/en unknown
- 2014-07-03 AU AU2014285052A patent/AU2014285052B2/en active Active
- 2014-07-03 JP JP2016524371A patent/JP6502337B2/ja active Active
- 2014-07-03 KR KR1020167002907A patent/KR102476907B1/ko active Active
- 2014-07-03 SG SG11201510618YA patent/SG11201510618YA/en unknown
- 2014-07-03 CN CN201480047723.5A patent/CN105492026B/zh active Active
- 2014-07-03 SG SG10201906172XA patent/SG10201906172XA/en unknown
- 2014-07-03 ES ES14820173T patent/ES2911690T3/es active Active
- 2014-07-03 TW TW109121891A patent/TWI753471B/zh active
- 2014-07-03 NZ NZ754427A patent/NZ754427A/en unknown
-
2018
- 2018-07-06 JP JP2018128766A patent/JP2018168186A/ja not_active Withdrawn
-
2019
- 2019-03-20 JP JP2019052046A patent/JP2019112455A/ja active Pending
- 2019-12-10 AU AU2019279945A patent/AU2019279945B2/en active Active
-
2020
- 2020-06-17 JP JP2020104177A patent/JP2020158525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201808451B (en) | Anti-fcrh5 antibodies | |
| SG11201509361TA (en) | Novel antibodies | |
| GB201322583D0 (en) | Antibodies | |
| PL2850101T3 (pl) | Przeciwciała anty-fcrn | |
| IL243355A0 (en) | Regulation of glucose metabolism using an anti-cgrp antibody | |
| ZA201506568B (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
| IL245265A0 (en) | Antibodies specific for fcrn | |
| ZA201601437B (en) | Antibodies | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| IL241410A0 (en) | Antibodies against cd–52 | |
| IL246276B (en) | Stem cells derived from mammalian muscles | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| GB201312226D0 (en) | Improved antibodies | |
| SI3016977T1 (sl) | Humana protitelesa proti IL-32 | |
| TWM475851U (en) | Structure of cane | |
| GB201318283D0 (en) | Antibodies |